Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 and -2 negative~* Good general health~* Fully circumcised~* Experienced one or both of the following HIV risk criteria in the 6 months before study entry:~  1. Unprotected anal intercourse with one or more male or MTF transgender partner(s)~ 2. Anal intercourse with two or more male or MTF transgender partners~* Alanine aminotransferase (ALT) 2.5 or less times the upper limit of normal (ULN)~* Ad5 neutralizing antibody (nAb) titer less than 1:18~* Have access to a participating study site and are willing to be followed during the study~* Demonstrate understanding of the study~* Willing to receive HIV test results~* Willing to discuss HIV infection risks and amenable to risk-reduction counseling~* Agrees not to enroll in another study of an investigational research agent before unblinding of this study~* NOTE: MTF transgender volunteers who have undergone gender reassignment surgery (GRS) are eligible to participate if they provide documentation from a health care provider confirming that they were fully circumcised prior to GRS. MTF transgender volunteers who have not undergone GRS are eligible to participate if they meet all enrollment criteria. Receipt of hormonal therapy does not make a transgender volunteer ineligible.~Exclusion Criteria:~* HIV vaccines in prior HIV vaccine trial. Participants who can provide documentation that they received a placebo in a prior HIV trial may be eligible.~* Used antiretroviral (ARV) drugs for the purpose of HIV-1 prophylaxis for greater than or equal to 50% of days during the 3 months prior to first vaccination or for 30 consecutive days within the 60 days prior to first vaccination~* Circumcised within 90 days prior to first vaccination or displays evidence that surgical site is not fully healed~* Immunosuppressive medications within 168 days prior to first study vaccination. Participants who have used corticosteroid nasal sprays for allergic rhinitis; topical corticosteroids for mild, uncomplicated dermatitis; or oral/parenteral corticosteroids for nonchronic conditions are not excluded.~* Blood products within 90 days prior to first study vaccination~* Immunoglobulin within 90 days prior to first study vaccination~* Live attenuated vaccines other than influenza vaccine within 30 days prior to first study vaccination~* Investigational research agents within 90 days prior to first study vaccination~* Influenza vaccine or any vaccines that are not live attenuated within 14 days prior to first study vaccination~* Allergy treatment with antigen injections within 30 days prior to first study vaccination or that are scheduled within 14 days after first vaccination~* Clinically significant medical condition, physical examination findings, abnormal laboratory results, or past medical history that, in the judgment of the investigator, has significant implications for current health~* Any medical, psychiatric, or job-related responsibility that would interfere with the study. More information about this criterion can be found in the protocol.~* Any concern that, in the opinion of the investigator, may interfere with a participant's completion of the post-vaccination symptom log~* History of serious adverse reactions to vaccinations, including anaphylaxis or allergy to any of the vaccine's components~* Current anti-tuberculosis prophylaxis or therapy~* Autoimmune disease. People with mild, stable, and uncomplicated autoimmune disease that does not require immunosuppressive medication and that, in the judgment of the site investigator, is likely not subject to exacerbation and likely not to complicate reactogenicity and adverse event assessments are not excluded.~* Immunodeficiency~* Bleeding disorder~* History of malignancy~* Seizure disorder. People with a history of seizures who have had no seizures within the 3 years prior to study entry are not excluded.~* Asthma other than mild, well-controlled asthma~* Hereditary angioedema (HAE), acquired angioedema (AAE), or idiopathic angioedema

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Participants will receive a recombinant DNA plasmid vaccine injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine injection on Day 168. As of April 2013, all vaccinations in this study have been stopped.
- 2 (Type: PLACEBO_COMPARATOR): Participants will receive a recombinant DNA plasmid vaccine placebo injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine placebo injection on Day 168. As of April 2013, all vaccinations in this study have been stopped.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy